Combination adefovir-lamivudine prevents emergence of adefovir resistance in lamivudine-resistant hepatitis B

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 9, 2007, Pages 1500-1505

  Van Der Poorten, David ^a   Prakoso, Emilia ^b   Khoo, Teh Liane ^a   Ngu, Meng C ^a   McCaughan, Geoffrey W ^b   Strasser, Simone I ^b   Lee, Alice U ^a  

^a ANZAC Research Institute   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Adefovir; Adefovir resistance; Hepatitis B; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; LAMIVUDINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUSTRALIA; BIOCHEMISTRY; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DATA ANALYSIS; DRUG TOLERANCE; FEMALE; HEPATITIS B; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE; VIROLOGY; VIRUS RESISTANCE;

EID: 34547971240     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05093.x     Document Type: Article

References (21)

1. Lai CL, Dienstag J, Schiff E et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 2003 36 : 687 96.
2. Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B [see comment]. Gastroenterology 2003 125 : 1714 22.
3. Perrillo R, Hann HW, Mutimer D et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004 126 : 81 90.
4. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 2003 348 : 800 7.
5. Marcellin P, Chang TT, Lim SG et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B [see comment]. N. Engl. J. Med. 2003 348 : 808 16.
6. Westland CE, Yang H, Delaney W et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003 38 : 96 103.
7. Yang H, Westland CE, Delaney W et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002 36 : 464 73.
8. Locarnini S, Qi X, Arterburn S et al. Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB) [Abstract]. J. Hepatol. 2005 42 : A32.
9. Craxi A, Antonucci G, Camma C. Treatment options in HBV. J. Hepatol. 2006 44 : S77 83.
10. Lok ASF, McMahon BJ. Chronic hepatitis B: update of recommendations. Hepatology 2004 39 : 857 61.
11. Fung SK, Chae HB, Fontana RJ et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J. Hepatol. 2006 44 : 283 90.
12. Lampertico P, Marzano A, Levrero M et al. A multicentre Italian study of rescue adefovir dipivoxil in lamivudine resistant patients; a 2-year analysis of 650 patients [Abstract]. J. Hepatol. 2006 44 : S51.
13. Lee YS, Suh DJ, Lim YS et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006 43 : 1385 91.
14. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N. Engl. J. Med. 2000 342 : 1266 71.
15. Snow A, Qi X, Zhu Y et al. Combination of adefovir (ADV) and lamivudine (LAM) prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-resistant HBV [Abstract]. Gastroenterology 2005 128 (Suppl. 2) : A745.
16. Bartholomeusz A, Locarnini SA. Antiviral drug resistance: clinical consequences and molecular aspects. Semin. Liver Dis. 2006 26 : 162 70.
17. Martin P. Role of combination therapy in chronic hepatitis B virus infection. Medsc. Gastroenterol. (Serial online) 2006 8. [Cited 16 May 2007.] Available from URL: http://www.medscape.com/viewarticle/536558
18. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 13.
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2005 352 : 2673 81.
20. Liaw YF, Lee CM, Chien RN, Yeh CT. Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis. J. Viral. Hepat. 2006 13 : 250 5.
21. Peters MG, Hann Hw H, Martin P et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B [see comment]. Gastroenterology 2004 126 : 91 101.